Sign in
Taking people in United StatesPhase 2

Fimepinostat as a possible treatment for Cushing disease

Tests 2 doses of fimepinostat in adults with Cushing disease.

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
16 Jan 2025
Expected to end
Jan 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fimepinostat
Record updated
17 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Cushing disease caused by a pituitary tumor. It can be new, ongoing or returned after surgery. The trial tests two doses of Fimepinostat for 4 weeks.

Age
18 years and older.
Sex
Men and women can join.
Disease stage
Cushing syndrome confirmed to come from the pituitary gland. This includes new disease, or disease that stayed or came back after pituitary surgery (24 hour UFC >ULN at least 4 weeks after surgery).
Earlier treatment
People taking medicines for Cushing disease must stop them before screening: metyrapone, ketoconazole, osilodristat, Levo-ketoconazole, pasireotide and mifepristone for 2 weeks, cabergoline for 4 weeks. No pituitary surgery or other major surgery within 1 month. No pituitary radiation in the last 5 years.
Biomarker or test result
Mean of 3 urine cortisol tests over 24h (UFC) ≥ 1.3x ULN. Normal or high blood ACTH. Pituitary adenoma > 4mm on MRI, or an IPSS ACTH gradient >2 at baseline and/or >2 after DDAVP.

Main reasons for not taking part

  • Vision problems, or a tumor touching or pressing the optic nerves
  • Cushing syndrome not caused by an ACTH-making pituitary tumor
  • Poorly controlled diabetes (HbA1c >8) or blood pressure ≥ 160/100 mm Hg
  • Serious heart, liver or kidney disease, HIV, hepatitis B or hepatitis C
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Male and female patients at least 18 years old
  • Patients with confirmed pituitary origin Cushing syndrome defined as 1, 2\& 3 or 4 \& 5 below:; Persistent hypercortisolism defined as a mean of 3 consecutive 24h UFC at baseline assessment ≥ 1.3x ULN; Normal or elevated plasma ACTH levels; Pituitary adenoma > 4mm visible on MRI or inferior petrosal sinus sampling (IPSS) central to peripheral ACTH gradient >2 at baseline and/or >2 after DDAVP stimulation; Recurrent or persistent CD defined as pathologically confirmed previously resected pituitary ACTH-secreting tumor, and 24 hour UFC >ULN at least 4 weeks after pituitary surgery; Patients on medical treatment for CD. Washout periods will be completed as below before screening: Inhibitors of steroidogenesis (metyrapone, ketoconazole, osilodristat,; Levo-ketoconazole): 2 weeks; SRLs (pasireotide): 2 weeks; Progesterone receptor antagonist (mifepristone): 2 weeks; Dopamine agonists (cabergoline): 4 weeks; CYP3A4 strong inducers or inhibitors: varies between drugs; minimum 5-6 times the half-life of drug

Who cannot take part

  • Patients who have undergone major surgery including pituitary surgery within 1 month of screening or who have any major surgical procedures planned across the study period
  • Patients not biochemically euthyroid. Patients receiving thyroid-replacement therapy must be on a stable dose for at least 3 months
  • Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to screening or within 5 half-lives of the investigational treatment whichever is longer
  • Patients with concomitant treatment of strong CYP3A4 inducers or inhibitors
  • Patients who have received pituitary irradiation within the last 5 years prior to the baseline visit
  • Patients with Cushing's syndrome not due to an ACTH-secreting pituitary tumor
  • Patients with poorly controlled hypertension (i.e. blood pressure ≥ 160/100 mm Hg)
  • Patients who have clinically significant cardiovascular impairment, as evidenced by the presence of bradycardia, ventricular tachycardia, history of myocardial infarction within past year, or any other cardiovascular impairment that may pose significant health risk in view of the investigator
  • Patients who are known to be positive for HIV, or any other condition that significantly compromises subject's immune system
  • History of alcohol abuse or illicit substance use within past year
  • Patients with known hepatitis B surface antigen (HbsAg) positivity
  • Patients with known hepatitis C antibody (anti-HCV) positivity
  • Patients with serum potassium < 3.5 mEq/L unless stably controlled on potassium supplementation
  • Patients with poorly-controlled Diabetes mellitus evidenced by HbA1c levels >8
  • Patients with liver disease or history of liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic persistent hepatitis, or patients with ALT or AST >1.5 x ULN, serum total bilirubin >ULN, serum albumin <0.67 x LLN at screening
  • Patients with renal disease or history of renal disease with creatinine clearance of 30 cm3/min or less and/or creatinine > 1.5 mg/dl at screening
  • Patients with compromised visual fields, or evidence of visual changes within past 6 months
  • Patients with sellar tumor abutting or compressing the optic chiasm on MRI and normal visual fields
  • Female patients who are pregnant or lactating or are of childbearing potential unless willing to practice acceptable method of birth control. Women participating in the trial must employ double barrier method through oral contraceptive or diaphragm with partner utilizing a condom. Abstinence is an acceptable form of birth control if routinely practiced. Male participants must utilize a condom with spermicidal cap/jelly and agree to not donate sperm for up to 3 months beyond main study period

Where in United States

  • Ronald Reagan Medical CenterLos Angeles, United StatesContact: Anthony Heaney, MDTaking people

About the trial

What the trial wants to find out

Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot, short-term (4 weeks) phase II single-center study to demonstrate the safety and efficacy of Fimepinostat in the treatment of patients with de novo, persistent, and/or recurrent CD recruited at the University of California, Los Angeles. The trial will have a 2-arm design and will simultaneously examine two different doses of Fimepinostat. The study will allow the investigators to determine the efficacy and safety of these doses in the treatment of CD and guide dose selection for subsequent, larger studies. Funding Source - FDA OOPD.

The 2 groups in the trial

  • Fimepinostat 60mgExisting treatment, for comparison

    two 30mg capsules once a day, 10 subjects

    Treatment: Fimepinostat

  • Fimepinostat 30mgExisting treatment, for comparison

    single 30mg capsule daily in 10 subjects

    Treatment: Fimepinostat

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Plain-language title
Fimepinostat as a possible treatment for Cushing diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
17 July 2026